Adolescents and Young Adults (AYA) have a high HIV incidence and poor outcomes along the entire HIV prevention and care cascades compared to adults. Despite the high HIV burden, both uptake of oral Pre-Exposure Prophylaxis (PrEP) (HIV negatives) and achieving viral suppression (HIV positives) are sub-optimal among youth in Sub-Saharan Africa. Among youth in Uganda, uptake and persistence on oral PrEP is low, with reasons for discontinuation including: pill burden, low perceived severity of HIV, need for partner or parental approval, HIV-related stigma, fear of side-effects and health facility barriers. Cabotegravir, a is new long-acting antiretroviral (CABLA) and highly efficacious PrEP choice that can mitigate barriers to use of daily oral PrEP. The Investigators propose to evaluate evidence-based HIV prevention and care interventions to improve implementation outcomes among high-risk AYA (15-24 years) in Uganda. The study covers the continuum of care, will use novel screening methods for HIV risk, will involve teams that are highly experienced in youth-focused clinical trials and Implementation Science (ImS), will implement Ministry of Health (MOH) approved community differentiated service delivery models for delivery CABLA, will evaluate the implementation of the Sustainable East Africa Research in Community Health (SEARCH) -Youth (SY), a multi-component intervention comprising of life-stage based assessment and support to increase viral suppression in high-risk AYA with HIV, and will use hybrid effectiveness implementation designs to assess these evidence-based interventions. The aims include: Aim 1: Using the Consolidated Framework for Implementation Research (CFIR), the investigators will identify determinants of potential implementation success of two innovations: CABLA and SY implementation at the community, clinic, provider, and patient levels in 5 geographically distinct sites in Uganda. Aim 2a: Using a hybrid effectiveness implementation type II design, the investigators will assess the uptake and persistence of CAB-LA. The investigators will conduct a randomized prospective study to assess effectiveness for the provision of CABLA among high risk AYA. Effectiveness outcome will be proportion of study subjects who have initiated CABLA and persisted at 18 months of follow-up comparing facility and community delivery options. Implementation outcomes will be feasibility, acceptability, adoption and maintenance using Reach Effectiveness Adoption Implementation Maintenance (REAIM). Aim 2b: Using a hybrid effectiveness implementation type III design the investigators will assess implementation (feasibility, adoption, fidelity, and sustainment) and effectiveness of the SY intervention in increasing long-term virologic suppression (\<200 c/mL) at 18 months of follow-up in 5 Clinical Research Performance Sites (CRPS) using REAIM. Aim 3: The investigators will use platforms in aims 1 and 2 to strengthen capacity of ImS and to translate findings into policy and guidelines. The study involves solid community and institutional partnerships and builds on a strong multi-disciplinary team highly experienced in innovative methods and implementation science in sub-Saharan Africa. The project, building on Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATC3H) and Adolescent HIV prevention and treatment implementation Science Alliance (AHISA), is responsive to World Health Organization's, Uganda's MoH priorities regarding the gap in HIV services for highly vulnerable AYA. It will test a novel, scalable and integrated approach to initiate and sustain support for high-risk AYA in Low and Middle Income Countries (LMICs).